Rapid Micro Biosystems helps businesses accelerate and automate their microbial quality control testing. The company has added new dates for their hands-on workshops in Bedford, Massachusetts. These hands on sessions allow microbial quality control specialists to speak directly with representatives of Rapid Micro Biosystems and interact with the new technology. Attendees learn the challenges impacting the adoption of rapid methods and how the Growth Direct™ technology addresses those challenges. Sessions are interactive and a full agenda is posted at the Rapid Micro Biosystems website.
Click here for dates and details >>
|
|
|
|
|
|
|
|
|
|
|
|
As the first multinational company to open a research centre in China in 1997, Novo Nordisk now reaffirms its long-term commitment to the country by investing an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing.
Read full story >>
|
|
 |
|
|
|
|
|
|
|
|
|
|
 Date: Thursday 27 September 2012
Time: 3pm BST
Length: 1 hour
In this one hour instructional webinar we will discuss how handheld Raman reduces costs and improves efficiency, the move to mandatory 100% testing of incoming raw materials, and recent developments in handheld Raman technology:
-
The move to mandatory 100% testing of incoming raw materials
Ravi Kalyanaraman PhD, Principal Scientist, Bristol Myers Squibb
-
How handheld Raman improves efficiency
John Kauffman, Research Chemist at FDA
-
Recent developments in handheld Raman and reducing costs
Enrique Lozano Diz PhD, Business Development
Manager, B&WTek
Just 48 hours to register >>
|
|
 Date: Thursday 18 October 2012
Time: 3pm BST
Length: 1 hour
A new family or Rapid Micro Method (RMM), real time viable particle detection based on Laser Induced Fluorescence (LIF), has recently been introduced. Sometimes referred to as optical spectroscopy, these instruments provide the ability to continuously measure for the presence of viable particles in real time.
During this webinar an overview of LIF technology will be presented, along with a detailed look at TSI’s implementation in the BioTrak® Real Time Viable Particle Detector highlighting critical instrument performance parameters.
Several application scenarios will be reviewed in the context of current regulatory initiatives such as QbD, ICH Q8, Q9, Q10 and PAT. These applications can form a framework of increased knowledge resulting in a better understanding of the manufacturing process leading to improved product quality in addition to financial benefits.
Register now >>
|
Featured news:
 Registration opens for Pittcon 2013
The Registration Committee is pleased to announce that conferee registration is now open for Pittcon 2013, which will be held March 17-21, 2013, at the Pennsylvania Convention Center, Philadelphia, PA.
|
Conferences, events & exhibitions:
Take Time to Make Time
26 September 2012 Dublin, Ireland
Biomarkers 2012
26 September 2012 London, UK
Joint EFGCP/DIA/EMA Medicines for Children Conference on Development of Paediatric Medicines: From Learning to Adapting
26 - 27 September 2012 London, UK
9th Confocal Raman Imaging Symposium
26 - 27 September 2012 Ulm, Germany
Next Generation Sequencing Asia Congress 2012
1 - 2 October 2012 Singapore
BIA UK Bioscience Forum
4 October 2012 London, UK
IFPAC Cortona Conference
7 - 10 October 2012 Cortona, Italy
Effective Internal and External Quality Assurance Auditing for FDA Regulated Industries
9 - 10 October 2012 Berlin, Germany
P-MEC Europe
9 - 11 October 2012 Madrid, Spain
2nd Annual Oncology Biomarkers Congress 2012
10 - 11 October 2012 Manchester, UK
1st International Genomics Research Asia
13 - 14 November 2012 Daejong, South Korea
|
|
Pharmaceuticals: Global Industry Almanac
The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million. In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
OTC Pharmaceuticals: Global Industry Almanac 2011
OTC Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology. Johnson & Johnson reported Remicade sales of $4.6bn in 2010, and the drug is the best-selling “biologic” in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.
|
|
|
